Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
23.63
+1.44 (6.49%)
At close: Dec 5, 2025, 4:00 PM EST
23.23
-0.40 (-1.69%)
After-hours: Dec 5, 2025, 7:59 PM EST
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 18 professional analysts, the 12-month price target for Apellis Pharmaceuticals stock ranges from a low of $18 to a high of $52. The average analyst price target of $33.11 forecasts a 40.12% increase in the stock price over the next year.
Price Target: $33.11 (+40.12%)
Analyst Consensus: Buy
* Price targets were last updated on Nov 5, 2025.
Analyst Ratings
The average analyst rating for Apellis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 4 | 4 | 4 |
| Buy | 6 | 7 | 7 | 7 | 7 | 6 |
| Hold | 9 | 10 | 9 | 8 | 9 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Total | 19 | 20 | 20 | 20 | 21 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 6, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $40 → $36 | Buy | Maintains | $40 → $36 | +52.35% | Nov 5, 2025 |
| Mizuho | Mizuho | Hold Maintains $24 → $19 | Hold | Maintains | $24 → $19 | -19.59% | Nov 3, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $52 → $45 | Strong Buy | Maintains | $52 → $45 | +90.44% | Oct 31, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $50 → $45 | Strong Buy | Maintains | $50 → $45 | +90.44% | Oct 31, 2025 |
Financial Forecast
Revenue This Year
1.01B
from 781.37M
Increased by 29.00%
Revenue Next Year
884.42M
from 1.01B
Decreased by -12.26%
EPS This Year
0.27
from -1.60
EPS Next Year
-1.12
from 0.27
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.0B | ||||
| Avg | 1.0B | 884.4M | ||||
| Low | 684.3M | 771.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 41.2% | -0.5% | ||||
| Avg | 29.0% | -12.3% | ||||
| Low | -12.4% | -23.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.50 | 0.44 | ||||
| Avg | 0.27 | -1.12 | ||||
| Low | 0.13 | -1.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 67.1% | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.